teva_RGB_JPEG.jpg
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET | Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Screenshot 2023-08-14 at 12.41.46 PM.png
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
September 20, 2024 16:05 ET | iBio, Inc.
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
Transaction in Own Shares
September 20, 2024 12:36 ET | Shell plc
Transaction in Own Shares 20 September, 2024 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 20 September 2024 it purchased the following number of Shares for...
stellantis-logo-white-background.jpg
Weekly Report (September 13-19, 2024) Third Tranche of Stellantis 2024 Share Buyback Program
September 20, 2024 11:49 ET | STELLANTIS N.V
Weekly Report (September 13-19, 2024) Third Tranche of Stellantis 2024 Share Buyback Program AMSTERDAM, September 20, 2024 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that...